Moleculin Biotech, Inc. provides an outlook and milestones for its drug candidates Annamycin and WP1066 in 2026.
Annamycin's pivotal Phase 2B/3 MIRACLE trial in AML and pancreatic cancer trial are key focuses.
WP1066, an immune/transcription modulator, aims to stimulate immune response in cancer treatment.
Annamycin Milestones
Potential as the world's first non-cardiotoxic anthracycline with significant market opportunity.
MIRACLE Trial Progress
Global expansion to nine countries with upcoming key milestones in 2026 and 2027.
Externally Funded Trials
Investigator-Initiated trials in pancreatic and brain cancer show strong interest in Moleculin's drug candidates.
- Moleculin's Annamycin presents a promising outlook with expected data readouts and global trial expansion.
- WP1066's design to target key oncogenic factors showcases innovative approaches in cancer treatment.
Moleculin's progress in advancing Annamycin and WP1066 positions the company for significant milestones and potential breakthroughs in cancer treatment.